PriceTargets.com logo

DiaMedica Therapeutics - DMAC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $12.33
  • Forecasted Upside: 42.91%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$8.63 As of 12/4/2025 05:00 PM ET
▲ +0.12 (1.41%)

This chart shows the closing price for DMAC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DiaMedica Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMAC

Analyst Price Target is $12.33
▲ +42.91% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for DiaMedica Therapeutics in the last 3 months. The average price target is $12.33, with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 42.91% upside from the last price of $8.63.

This chart shows the closing price for DMAC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 polled investment analysts is to moderate buy stock in DiaMedica Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2025Cantor FitzgeraldInitiated CoverageOverweight
10/30/2025CowenInitiated CoverageBuy
10/30/2025TD CowenInitiated CoverageBuy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$12.00
7/18/2025Lake Street CapitalBoost TargetBuy ➝ Buy$11.00 ➝ $14.00
7/18/2025Craig HallumBoost TargetBuy ➝ Buy$8.00 ➝ $11.00
7/18/2025HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $12.00
5/29/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00
3/19/2025HC WainwrightBoost TargetBuy ➝ Buy$7.00 ➝ $10.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
10/7/2024HC WainwrightInitiated CoverageBuy ➝ Buy$7.00 ➝ $7.00
8/16/2024OppenheimerReiterated RatingOutperform ➝ Outperform$6.00 ➝ $6.00
4/24/2024Craig HallumInitiated CoverageBuy$8.00
3/21/2024Craig HallumLower TargetBuy ➝ Buy$11.00 ➝ $8.00
3/21/2024OppenheimerReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.00
6/22/2023OppenheimerUpgradeMarket Perform ➝ Outperform$7.00
7/7/2022Lake Street CapitalLower TargetBuy$14.00 ➝ $8.00
7/7/2022Craig HallumLower TargetBuy$18.00 ➝ $12.00
7/7/2022OppenheimerDowngradeOutperform ➝ Market Perform
9/27/2021Roth CapitalLower TargetBuy$32.00 ➝ $24.00
6/30/2021Maxim GroupLower TargetBuy$14.00 ➝ $11.00
6/29/2021Roth CapitalLower TargetBuy$38.00 ➝ $32.00
4/8/2021OppenheimerInitiated CoverageOutperform$27.00
3/15/2021Craig HallumBoost Target$15.00 ➝ $20.00
2/17/2021Roth CapitalInitiated CoverageBuy$38.00
1/4/2021Lake Street CapitalBoost TargetBuy$14.00 ➝ $28.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

DiaMedica Therapeutics logo
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $8.63
Low: $7.97
High: $8.88

50 Day Range

MA: $7.08
Low: $5.42
High: $9.12

52 Week Range

Now: $8.63
Low: $3.19
High: $9.23

Volume

335,609 shs

Average Volume

520,772 shs

Market Capitalization

$449.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of DiaMedica Therapeutics?

The following sell-side analysts have issued reports on DiaMedica Therapeutics in the last twelve months: Cantor Fitzgerald, Cowen Inc, Craig Hallum, HC Wainwright, Lake Street Capital, TD Cowen, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for DMAC.

What is the current price target for DiaMedica Therapeutics?

0 Wall Street analysts have set twelve-month price targets for DiaMedica Therapeutics in the last year. Their average twelve-month price target is $12.33, suggesting a possible upside of 42.9%. Lake Street Capital has the highest price target set, predicting DMAC will reach $14.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $11.00 for DiaMedica Therapeutics in the next year.
View the latest price targets for DMAC.

What is the current consensus analyst rating for DiaMedica Therapeutics?

DiaMedica Therapeutics currently has 1 sell rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DMAC.

What other companies compete with DiaMedica Therapeutics?

Other companies that are similar to DiaMedica Therapeutics include Agios Pharmaceuticals, Trevi Therapeutics, Immunome, Syndax Pharmaceuticals and uniQure. Learn More about companies similar to DiaMedica Therapeutics.

How do I contact DiaMedica Therapeutics' investor relations team?

DiaMedica Therapeutics' physical mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company's listed phone number is (763) 496-5454 and its investor relations email address is [email protected]. The official website for DiaMedica Therapeutics is www.diamedica.com. Learn More about contacing DiaMedica Therapeutics investor relations.